These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38321099)

  • 1. The association between tocilizumab therapy and the development of thrombosis in critically ill patients with COVID-19: a multicenter, cohort study.
    Aljuhani O; Al Sulaiman K; Korayem GB; Altebainawi AF; Alsohimi S; Alqahtani R; Alfaifi S; Alharbi A; AlKhayrat A; Hattan A; Albassam M; Almohammed OA; Alkeraidees A; Alonazi DA; Alsalman WF; Aldamegh G; Alshahrani R; Vishwakarma R
    Sci Rep; 2024 Feb; 14(1):3037. PubMed ID: 38321099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.
    Gupta S; Wang W; Hayek SS; Chan L; Mathews KS; Melamed ML; Brenner SK; Leonberg-Yoo A; Schenck EJ; Radbel J; Reiser J; Bansal A; Srivastava A; Zhou Y; Finkel D; Green A; Mallappallil M; Faugno AJ; Zhang J; Velez JCQ; Shaefi S; Parikh CR; Charytan DM; Athavale AM; Friedman AN; Redfern RE; Short SAP; Correa S; Pokharel KK; Admon AJ; Donnelly JP; Gershengorn HB; Douin DJ; Semler MW; Hernán MA; Leaf DE;
    JAMA Intern Med; 2021 Jan; 181(1):41-51. PubMed ID: 33080002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Early Tocilizumab Effect on Multiorgan Dysfunction in Critically Ill Patients With COVID-19: A Propensity Score-Matched Study.
    Aljuhani O; Korayem GB; Altebainawi AF; Al Harthi A; Badreldin HA; Alsalloum MA; Eljaaly K; Alharbi A; Aljehani R; Vishwakarma R; Alenazi AA; Alalawi M; Alissa A; Al Aamer K; Al Enazi H; Almusallam M; Alshehri A; Bukhari R; Alasmari G; AlQahtani MM; Al Shammari S; Alsulaymi HO; Al Sulaiman K
    J Intensive Care Med; 2023 Jun; 38(6):534-543. PubMed ID: 36683420
    [No Abstract]   [Full Text] [Related]  

  • 4. Statins and Risk of Thrombosis in Critically ill Patients with COVID-19: A Multicenter Cohort Study.
    Al Harbi S; Kensara R; Aljuhani O; Korayem GB; Altebainawi AF; Al Harthi A; Vishwakarma R; Alenazi AM; Almutairi A; Alshaya O; Alraddadi S; Al Sulaiman T; Aldakkan L; Mahboob R; Alaamer K; Alissa A; Hafiz A; Aldhayyan N; Althewaibi S; Alenezi F; Alkhotani NY; Alghamdi SA; Alenazi AA; Al Sulaiman K
    Clin Appl Thromb Hemost; 2022; 28():10760296221103864. PubMed ID: 35658686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and effectiveness of tocilizumab in older adult critically ill patients with COVID-19: a multicenter, cohort study.
    Korayem GB; Aljuhani O; Altebainawi AF; Shaya AIA; Alnajjar LI; Alissa A; Aldhaeefi M; Kensara R; Al Muqati H; Alhuwahmel A; Alhuthaili O; Vishwakarma R; Aldardeer N; Eljaaly K; Alharbi A; Harbi SA; Katheri AA; Bekairy AMA; Aljedai A; Al Sulaiman K
    Int J Infect Dis; 2022 Sep; 122():252-259. PubMed ID: 35605948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis.
    Urbina T; Lavillegrand JR; Garnier M; Mekinian A; Pacanowski J; Mario N; Dumas G; Hariri G; Pilon A; Darrivère L; Fartoukh M; Guidet B; Maury E; Leblanc J; Chantran Y; Fain O; Lacombe K; Voiriot G; Ait-Oufella H
    Innate Immun; 2022 Jan; 28(1):3-10. PubMed ID: 35089113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics.
    Elhazmi A; Rabie AA; Al-Omari A; Mufti HN; Sallam H; Alshahrani MS; Mady A; Alghamdi A; Altalaq A; Azzam MH; Sindi A; Kharaba A; Al-Aseri ZA; Almekhlafi GA; Tashkandi W; Alajmi SA; Faqihi F; Alharthy A; Al-Tawfiq JA; Melibari RG; Arabi YM
    J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study.
    Al Sulaiman K; Aljuhani O; Al Dossari M; Alshahrani A; Alharbi A; Algarni R; Al Jeraisy M; Al Harbi S; Al Katheri A; Al Eidan F; Al Bekairy AM; Al Qahtani N; Al Muqrin M; Vishwakarma R; Al Ghamdi G
    Crit Care; 2021 Jun; 25(1):223. PubMed ID: 34193235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of Tocilizumab in COVID-19 critically ill patients with renal impairment: a multicenter, cohort study.
    Aljuhani O; Al Sulaiman K; B Korayem G; Alharbi A; Altebainawi AF; Aldkheel SA; Alotaibi SG; Vishwakarma R; Alshareef H; Alsohimi S; AlFaifi M; Al Shaya A; Alhaidal HA; Alsubaie RM; Alrashidi H; Albarqi KJ; Alangari DT; Alanazi RM; Altaher NM; Al-Dorzi HM
    Ren Fail; 2023; 45(2):2268213. PubMed ID: 37870869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single versus multiple doses of Tocilizumab in critically ill patients with coronavirus disease 2019 (COVID-19): A two-center, retrospective cohort study.
    Al Sulaiman K; Aljuhani O; Bin Salah K; Korayem GB; Eljaaly K; Al Essa M; Kharbosh A; Al Harbi F; Abuzaid M; Al Bilal S; Almagthali A; Alsohemi S; Alshabasy A; Noureldeen H; Aboudeif M; Alshehri A; Vishwakarma R
    J Crit Care; 2021 Dec; 66():44-51. PubMed ID: 34438133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study.
    Al Harthi AF; Aljuhani O; Korayem GB; Altebainawi AF; Alenezi RS; Al Harbi S; Gramish J; Kensara R; Hafidh A; Al Enazi H; Alawad A; Alotaibi R; Alshehri A; Alhuthaili O; Vishwakarma R; Bin Saleh K; Alsulaiman T; Alqahtani RA; Hussain S; Almazrou S; Al Sulaiman K
    J Intensive Care Med; 2022 Sep; 37(9):1238-1249. PubMed ID: 35450493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxycycline's Potential Role in Reducing Thrombosis and Mortality in Critically Ill Patients With COVID-19: A Multicenter Cohort Study.
    Al Sulaiman K; Aljuhani O; Korayem GB; Alnajjar LI; Altebainawi AF; AlFaifi M; Vishwakarma R; Alenazi AA; Alalawi M; Alissa A; Alsowaida YS; Alsohimi S; Almagthali A; Alay SM; Altaher N; Alamri MG; Alangari D; Alzahrani A; Abdul Razack HI; Alhamoud J; Alshaya A; Gramish J; Al Aamer K; Alsaeedi AS; Alghamdi G
    Clin Appl Thromb Hemost; 2023; 29():10760296231177017. PubMed ID: 37322869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: a multicenter cohort study.
    Al Sulaiman K; Korayem GB; Altebainawi AF; Al Harbi S; Alissa A; Alharthi A; Kensara R; Alfahed A; Vishwakarma R; Al Haji H; Almohaimid N; Al Zumai O; Alrubayan F; Asiri A; Alkahtani N; Alolayan A; Alsohimi S; Melibari N; Almagthali A; Aljahdali S; Alenazi AA; Alsaeedi AS; Al Ghamdi G; Al Faris O; Alqahtani J; Al Qahtani J; Alshammari KA; Alshammari KI; Aljuhani O
    Crit Care; 2022 Oct; 26(1):304. PubMed ID: 36192801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When antivirals backfire: An evaluation of favipiravir's clinical outcomes in critically ill patients with COVID-19: A multicenter cohort study.
    Al Sulaiman K; Aljuhani O; Korayem GB; Altebainawi AF; AlFaifi M; Nahari M; Almagthali A; Thabit AK; Alhajaji R; Alharbi R; Kahtani K; Alenazi AA; Alharbi A; Alghwainm MM; Alotaibi SM; Alghamdi YS; Alotaibi S; Alonazi SH; Almutairi JM; Vishwakarma R
    J Infect Public Health; 2023 Sep; 16(9):1492-1499. PubMed ID: 37355406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study.
    Al Sulaiman K; Aljuhani O; Korayem GB; Hafiz A; Alalawi M; Badreldin HA; Altebainawi AF; Vishwakarma R; Alissa A; Alghamdi A; Alenazi AA; Al Enazi H; Alanazi S; Alhammad A; Alghamdi J; AlFaifi M; Al Sehli FA; Aldossari MA; Alhubaishi AA; Al-Ali AY; Al-Dorzi HM
    Thromb J; 2022 Dec; 20(1):74. PubMed ID: 36482388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab: A retrospective multi-center cohort study of critically ill patients with COVID-19.
    Villatoro Santos CR; Bhargava A; Coyle M; Szpunar S; Saravolatz LD
    Int J Clin Pharmacol Ther; 2021 Nov; 59(11):705-712. PubMed ID: 34448693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
    Ip A; Berry DA; Hansen E; Goy AH; Pecora AL; Sinclaire BA; Bednarz U; Marafelias M; Berry SM; Berry NS; Mathura S; Sawczuk IS; Biran N; Go RC; Sperber S; Piwoz JA; Balani B; Cicogna C; Sebti R; Zuckerman J; Rose KM; Tank L; Jacobs LG; Korcak J; Timmapuri SL; Underwood JP; Sugalski G; Barsky C; Varga DW; Asif A; Landolfi JC; Goldberg SL
    PLoS One; 2020; 15(8):e0237693. PubMed ID: 32790733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baricitinib versus tocilizumab in critically ill COVID-19 patients: A retrospective cohort study.
    Conroy GM; Bauer SR; Pallotta AM; Duggal A; Wang L; Sacha GL
    Pharmacotherapy; 2024 Jan; 44(1):28-38. PubMed ID: 37593883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study.
    Aljuhani O; Al Sulaiman K; Alshabasy A; Eljaaly K; Al Shaya AI; Noureldeen H; Aboudeif M; Al Dosari B; Alkhalaf A; Korayem GB; Aleissa MM; Badreldin HA; Al Harbi S; Alhammad A; Vishwakarma R
    BMC Infect Dis; 2021 Nov; 21(1):1127. PubMed ID: 34724920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia.
    Cardona-Pascual I; Berlana D; Martinez-Valle F; Campany-Herrero D; Montoro-Ronsano JB
    Med Clin (Barc); 2022 Apr; 158(7):301-307. PubMed ID: 34147248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.